Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 19/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 18/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253822 | 0.87 | HCRTR1 (0.80) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL2279413 | 0.87 | HCRTR2 (0.64) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL2278357 | 0.85 | HCRTR2 (0.67) | HCRTR2HCRTR1KCNH2HTR1AOPRM1 | |
| SCHEMBL2282900 | 0.81 | HCRTR1 (0.75) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL2279807 | 0.79 | HCRTR2 (0.45) | HCRTR2HCRTR1 | |
| SCHEMBL8082692 | 0.79 | HCRTR1 (0.82) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL3486955 | 0.78 | HCRTR2 (0.75) | HCRTR2HCRTR1KCNH2HTR1AOPRM1 | |
| SCHEMBL13498691 | 0.77 | HCRTR2 (0.70) | HCRTR2HCRTR1KCNH2HTR1AOPRM1 | |
| SCHEMBL8087616 | 0.76 | DHODH (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL2277636 | 0.76 | HCRTR1 (1.00) | HCRTR2HCRTR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003797-B2 | Pyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003797-B2 | Pyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR2 1/4885HCRTR1 2/4885KCNH2 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.